McGuire Annie sold $140K of VCYT
McGuire Annie (EVP, General Counsel) sold 3,254 shares of VERACYTE, INC. (VCYT) at an average of $43.09 ($42.79–$43.67, $0.14M total) across 2 trades on 2026-09-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is modest and pre‑arranged, offering limited trading insight.
Market read
Minor insider sell; unlikely to affect market perception or price.
What to watch
Potential upcoming corporate actions or personal tax planning not disclosed.
Background
Form 4 filings disclose insider trades; VCYT is a Nasdaq-listed molecular diagnostics company.
Ticker impact
Officer sold $140K of shares via 10b5-1 plan, reducing holdings to 131,160 shares.
minimal short-term price pressure, likely within normal volatility.
Sale size is small relative to market cap; typical for 10b5-1 plans, unlikely to move price materially.
Market effects
No broader sector impact; isolated insider transaction.
Limited to US biotech market, negligible.
None.
Counterpoint
The sale could be a routine liquidity event, not a negative signal.
Key entities
- CompanyVeracyte, Inc.
NASDAQ-listed molecular diagnostics firm.
- InsiderAnnie McGuire
Executive Vice President, General Counsel.